Diversity of signaling underlying responses mediated by selective activation of the platelet thromboxane A2 (TXA2) receptor; pharmacological and kinetic studies in vitro

Platelets

Volumn 14, Issue 6, 2003, Pages 359-374

  Maayani, Saul ^a   Schwarz, Todd E ^a   Patel, Nayana D ^a   Craddock Royal, Barbara D ^a   Tagliente, Thomas M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 9 (TETRAHYDRO 2 FURYL)ADENINE; ADENYLATE CYCLASE; ADRENALIN; ALPHA 2A ADRENERGIC RECEPTOR; G PROTEIN COUPLED RECEPTOR; SULPROSTONE; THROMBOXANE A2 RECEPTOR; WORTMANNIN;

ARTICLE; BLOOD VESSEL INJURY; COMPLEX FORMATION; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; HEMOSTASIS; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REGULATORY MECHANISM; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TURBIDIMETRY;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANDROSTADIENES; ASPIRIN; BLOOD PLATELETS; CELL SIZE; EPINEPHRINE; HUMANS; KINETICS; PLATELET ACTIVATION; PLATELET AGGREGATION; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; REFERENCE VALUES;

EID: 0347506754     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/09537100310001612380     Document Type: Article

References (91)

1. Abrams C S, Brass L F. Platelet signal transduction. In: Colman R W, Hirsh J, Marder V J, Clows A W, George J N, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Baltimore, MD: Lippincott Williams & Wilkins, 2001: 541-59.
2. Woulfe D, Yang J, Prevost N, O'Brien P J, Brass L F. Signal transduction during the initiation, extension and perpetuation of platelet plug formation. In: Michelson A D, ed. Platelets. New York: Academic Press, 2002: 197-214.
3. Dorn G W 2nd, De Jesus A. Human platelet aggregation and shape change are coupled to separate thromboxane A2-prostaglandin H2 receptors. Am J Physiol 1991; 260: H327-34.
4. 2+ pathway in rabbit platelets. Br J Pharmacol 1996; 117: 1095-104.
5. Hirata T, Ushikubi F, Kakizuka A, Okuma M, Narumiya S. Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. J Clin Invest 1996; 97: 949-56.
6. Habib A, FitzGerald G A, Maclouf J. Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets. J Biol Chem 1999; 274: 2645-51.
7. Shenker A, Goldsmith P, Unson C G, Spiegel A M. The G-protein coupled to the thromboxane-A2 receptor in human platelets is a member of the novel Gq family. Journal of Biological Chemistry 1991; 266: 9309-13.
8. Offermanns S, Laugwitz K L, Spicher K, Schultz G. G-proteins of the G(12) family are activated via thromboxane a(2) and thrombin receptors in human platelets. Proc Natl Acad Sci USA 1994; 91: 504-8.
9. Offermanns S, Toombs C F, Hu Y H, Simon M I. Defective platelet activation in G alpha(q)-deficient mice. Nature 1997; 389: 183-6.
10. Klages B, Brandt U, Simon M I, Schultz G, Offermanns S. Activation of G12/G13 results in shape change and Rho/Rhokinase-mediated myosin light chain phosphorylation in mouse platelets. J Cell Biol 1999; 144: 745-54.
11. Bauer M, Retzer M, Wilde J I, Maschberger P, Essler M, Aepfelbacher M, et al. Dichotomous regulation of myosin phosphorylation and shape change by Rho-kinase and calcium in intact human platelets. Blood 1999; 94: 1665-72.
12. Paul B Z, Jin J, Kunapuli S P. Molecular mechanism of thromboxane A(2)-induced platelet aggregation. Essential role for p2t(ac) and alpha(2a) receptors. J Biol Chem 1999; 274: 29108-14.
13. Offermanns S. The role of heterotrimeric G proteins in platelet activation. Biol Chem 2000; 381: 389-96.
14. Missy K, Plantavid M, Pacaud P, Viala C, Chap H, Payrastre B. Rho-kinase is involved in the sustained phosphorylation of myosin and the irreversible platelet aggregation induced by PARI activating peptide. Thromb Haemost 2001; 85: 514-20.
15. Gratacap M P, Payrastre B, Nieswandt B, Offermanns S. Differential regulation of Rho and Rac through heterotrimeric G-proteins and cyclic nucleotides. J Bio Chem 2001; 276: 47906-13.
16. Nieswandt B, Schulte V, Zywietz A, Gratacap M P, Offermanns S. Costimulation of G(i)-and G(12)/G(13)-mediated signaling pathways induces integrin alpha(IIb) beta(3) activation in platelets. J BM Chem 2002; 277: 39493-8.
17. Jin J, Kunapuli S P. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci USA 1998; 95: 8070-4.
18. Pulcinelli F M, Pesciotti M, Pignatelli P, Riondino S. Gazzaniga PP. Concomitant activation of Gi and Gq protein-coupled receptors does not require an increase in cytosolic calcium for platelet aggregation. FEBS Lett 1998; 435: 115-8.
19. Dangelmaier C, Jin J G, Smith J B, Kunapuli S P. Potentiation of thromboxane A(2)-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway. Thromb Haemost 2001; 85: 341-8.
20. Li Z, Zhang G, Le Breton G C, Gao X, Malik A B, Du X. Two waves of platelet secretion induced by thromboxane A2 receptor, and a critical role for phosphoinositide 3-kinases. J Biol Chem 2003; 278: 30725-31.
21. Storey R F, Sanderson H M, White A E, May J A, Cameron K E, Heptinstall S. The central role of the P-2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000; 110: 925-34.
22. Storey R F, Newby L J, Heptinstall S. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 2001; 12: 443-7.
23. Keularts I M, van Gorp R M, Feijge M A, Vuist W M, Heemskerk J W. Alpha(2A)-adrenergic receptor stimulation potentiates calcium release in platelets by modulating cAMP levels. J Biol Chem 2000; 275: 1763-72.
24. Rittenhouse S E. Phosphoinositide 3-kinase activation and platelet function. Blood 1996; 88: 4401-14.
25. Selheim F, Froyset A K, Strand I, Vassbotn F S, Holmsen H. Adrenaline potentiates PI 3-kinase in platelets stimulated with thrombin and SFRLLN: role of secreted ADP. FEBS Lett 2000; 485: 62-6.
26. Selheim F, Holmsen H, Vassbotn F S. PI 3-kinase signalling in platelets: the significance of synergistic, autocrine stimulation. Platelets 2000; 11: 69-82.
27. Payrastre B, Gratacap M-P, Trumel C, Missy K, Chap H, Gachet C, et al. ADP: an important cofactor of PI 3-kinase activation in human blood platelets. Haematologica 2000; 85: 32-6.
28. Payrastre B, Missy K, Trumel C, Bodin S, Plantavid M, Chap H. The integrin alpha IIb/beta 3 in human platelet signal transduction. Biochem Pharmacol 2000; 60: 1069-74.
29. Maayani S, Patel N D, Craddock-Royal B, Schwarz T E, Tagliente T M. Concurrent responses elicited by isolated activation of platelet Gq-coupled receptors, in vitro: a novel approach for their separation and analysis. Platelets 2003; 14: 89-102.
30. Maayani S, Tagliente T M, Schwarz T, Martinelli G, Martinez R, Shore-Lesserson L. The balance of concurrent aggregation and deaggregation processes in platelets is linked to differential occupancy of ADP receptor subtypes. Platelets 2001; 12: 83-93.
31. Maayani S, Tagliente T M, Schwarz T, Craddock-Royal B, Alcala C, Marrero G, et al. Deaggregation is an integral component of the response of platelets to ADP in vitro: kinetic studies of literature and original data. Platelets 2001; 12: 279-91.
32. Maayani S, Schwarz T, Craddock-Royal B, Tagliente T M. Activation of the alpha(2A)-adrenoceptor mediates deceleration of the deaggregation component of the response to ADP or 5-HT in human platelets in vitro. Platelets 2001; 12: 359-75.
33. Maayani S, Schwarz T, Martinez R, Tagliente T M. Activation of Gi-coupled receptors releases a tonic state of inhibited platelet aggregation. Platelets 2001; 12: 94-8.
34. Ozaki Y, Satoh K, Yatomi Y, Yamamoto T, Shirasawa Y, Kume S. Detection of platelet aggregates with a particle counting method using light scattering. Anal Biochem 1994; 218: 284-94.
35. Yamamoto T, Egawa Y, Shirasawa Y, Ozaki Y, Sato K, Yatomi Y, et al. A laser light scattering in situ system for counting aggregates in blood platelet. Meas Sci Technol 1995; 6; 174-80.
36. Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000; 111: 733-44.
37. Ryningen A, Holmsen H. Role of autocrine stimulation for the effects of cyclic AMP on protein and lipid phosphorylation in platelets activated by particles. FEBS Lett 1998; 436: 335-8.
38. Ryningen A, Jensen B O, Holmsen H. Role of autocrine stimulation on the effects of cyclic AMP on protein and lipid phosphorylation in collagen-activated and thrombin-activated platelets. Eur J Biochem 1999; 260: 87-96.
39. Fagura M S, Dainty I A, McKay G D, Kirk I P, Humphries R G, Robertson M J, et al. P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors. Br J Pharmacol 1998; 124: 157-64.
40. Fukami M H, Holmse H, Kowalska M A, Niewiarowski S. Platelet secretion. In: Colman R W, Hirsh J, Marder V J, Clowes A W, George J N, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th edn. Baltimore, MD: Lippincott Williams and Wilkins, 2001: 561-73.
41. Boyer J L, Romero-Avila T, Schachter J B, Harden T K. Identification of competitive antagonists of the P2Y1 receptor. Mol Pharmacol 1996; 50: 1323-9.
42. Gaddum J H. Biological aspects: the antagonism of drugs. Trans. Faraday Soc. 1943; 39: 323-33.
43. Gaddum J H. Theories of drug antagonism. Pharmacol Rev 1957; 9: 211-8.
44. De Clerck F, Xhonneux B, Leysen J, Janssen P A. Evidence for functional 5-HT2 receptor sites on human blood platelets. Biochem Pharmacol 1984; 33: 2807-11.
45. Eto K, Takeshita S, Ochiai M, Ozaki Y, Sato T, Isshiki T. Platelet aggregation in acute coronary syndromes: use of a new aggregometer with laser light scattering to assess platelet aggregability. Cardiovasc Res 1998; 40: 223-9.
46. Hause L L, Retzinger G S, Megan P A. A compartmental model of platelet aggregation in vitro: the kinetics of single platelets. Thromb Res 1989; 56: 133-46.
47. Wachsman D E, Kavaler J P, Sugar I P, Schachter E N, Gonsiorek W, Maayani S. Kinetic studies of desensitization and resensitization of the relaxation response to beta-2 adrenoceptor agonists in isolated guinea pig trachea. J Pharmacol Exp Ther 1997; 280: 332-45.
48. Cheng Y, Prusoff W H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099-108.
49. Anfossi G, Trovati M. Role of catecholamines in platelet function: pathophysiological and clinical significance. Eur J Clin Invest 1996; 26: 353-70.
50. Matthews J S, Jones R L. Potentiation of aggregation and inhibition of adenylate-cyclase in human platelets by prostaglandin-E analogs. Br J Pharmacol 1993; 108: 363-9.
51. Fabre J-E, Nguyen M, Athirakul K, Coggins K, McNeish J D, Austin S, et al. Activation of the murine EP3 receptor for PGE(2) inhibits cAMP production and promotes platelet aggregation. J Clin Invest 2001; 107: 603-10.
52. Lanza F, Beretz A, Stierle A, Hanau D, Kubina M, Cazenave J P. Epinephrine potentiates human platelet activation but is not an aggregating agent. Am J Physiol 1988; 255: H1276-88.
53. Steen V M, Holmsen H, Aarbakke G. The platelet-stimulating effect of adrenaline through alpha 2-adrenergic receptors requires simultaneous activation by a true stimulatory platelet agonist. Evidence that adrenaline per se does not induce human platelet activation in vitro. Thromb Haemost 1993; 70: 506-13.
54. Haslam R J, Davidson M M, Desjardins J V. Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Evidence for the unidirectional control of platelet function by cyclic AMP. Biochem J 1978; 176: 83-95.
55. Katsel P L, Tagliente T M, Schwartz T E, Craddock-Royal B D, Patel N D, Maayani S. Molecular and biochemical evidence for the presence of type III adenylyl cyclase in human platelets. Platelets 2003; 14: 21-33.
56. Hei Y J, MacDonell K L, McNeill J H, Diamond J. Lack of correlation between activation of cyclic AMP-dependent protein kinase and inhibition of contraction of rat vas deferens by cyclic AMP analogs. Mol Pharmacol 1991; 39: 233-8.
57. Trumel C, Payrastre B, Plantavid M, Hechler B, Viala C, Presek P, et al. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood 1999; 94: 4156-65.
58. Wilde J I, Retzer M, Siess W, Watson S P. ADP-induced platelet shape change: an investigation of the signalling pathways involved and their dependence on the method of platelet preparation. Platelets 2000; 11: 286-95.
59. Dorn G W 2nd, Becker M W. Thromboxane A2 stimulated signal transduction in vascular smooth muscle. J Pharmacol Exp Ther 1993; 265: 447-56.
60. Hirata M, Hayashi Y, Ushikubi F, Yokota Y, Kageyama R, Nakanishi S, et al. Cloning and expression of cDNA for a human thromboxane-A2 receptor. Nature 1991; 349: 617-20.
61. Brass L F, Manning D R, Cichowski K, Abrams C S. Signaling through G proteins in platelets: to the integrins and beyond. Thromb Haemost 1997; 78: 581-9.
62. Kovacsovics T J, Bachelot C. Toker A, Vlahos C J, Duckworth B, Cantley L C, et al. Phosphoinositide 3-kinase inhibition spares actin assembly in activating platelets but reverses platelet aggregation. J Biol Chem 1995; 270: 11358-66.
63. Maayani S, Patel N D, Craddock-Royal B, Schwarz T E, Tagliente T M. Agonist concentration dependent differential responsivity of a human platelet purinergic receptor; pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro. Platelets 2003; (in press).
64. Savi P, Pflieger A M, Herbert J M. cAMP is not an important messenger for ADP-induced platelet aggregation. Blood Coagul Fibrinolysis 1996; 7: 249-52.
65. Weber A-A, Hohlfeld T, Schror K. cAMP is an important messenger for ADP-induced platelet aggregation. Platelet 1999; 10: 238-41.
66. Maayani S, Schwarz T E, Craddock-Royal B, Patel N D, Tagliente T M. Bi-directional modulation of platelet function by adenylyl cycclase. IV. Agents that affect intracellular cAMP levels influence platelet function through acceleration or deceleration of deaggregation in vitro. Blood 2001; 98: 47b.
67. Yang J, Wu J, Kowalska M A, Dalvi A, Prevost N, O'Brien P J, et al. Loss of signaling through the G protein, Gz, results in abnormal platelet activation and altered responses to psychoactive drugs. Proc Natl Acad Sci USA 2000; 97: 9984-9.
68. Sheu J R, Hsiao G, Shen M Y, Lin W Y, Tzeng C R. The hyperaggregability of platelets from normal pregnancy is mediated through thromboxane A2 and cyclic AMP pathways. Clin Lab Haematol 2002; 24: 121-9.
69. Schwarz T E, Maayani S, Craddock-Royal B, Patel N D, Tagliente T M. Bi-directional modulation of platelet function by adenylyl cycclase. III. Non-receptor-mediated inhibition of platelet adenylyl cyclase activity increased stability of transient aggregates formed in vitro through activation of Gq-coupled receptors. Blood 2001; 98: 45b.
70. Suzuki Y, Yamamoto M, Wada H, Ito M, Nakano T, Sasaki Y. et al. Agonist-induced regulation of myosin phosphatase activity in human platelets through activation of Rho-kinase. Blood 1999; 93: 3408-17.
71. Dong J M, Leung T, Manser E, Lim L. cAMP-induced morphological changes are counteracted by the activated RhoA small GTPase and the Rho kinase ROKalpha. J Biol Chem 1998; 273: 22554-62.
72. Thomason P A, James S R, Casey P J, Downes C P. A G-protein beta gamma-subunit-responsive phosphoinositide 3-kinase activity in human platelet cytosol. J Biol Chem 1994; 269: 16525-8.
73. Zhang J, Benovic J L, Sugai M, Wetzker R, Gout I, Rittenhouse S E. Sequestration of a G-protein beta gamma subunit or ADP-ribosylation of Rho can inhibit thrombin-induced activation of platelet phosphoinositide 3-kinases. J Biol Chem 1995; 270: 6589-94.
74. Zhang J, Shattil S J, Cunningham M C, Rittenhouse S E. Phosphoinositide 3-kinase gamma and p85/phosphoinositide 3-kinase in platelets. Relative activation by thrombin receptor or beta-phorbol myristate acetate and roles in promoting the ligand-binding function of alphaIIbeta3 integrin. J Biol Chem 1996; 271: 6265-72.
75. Tang X, Downes C P. Purification and characterization of Gbetagamma-responsive phosphoinositide 3-kinases from pig platelet cytosol. J Biol Chem 1997; 272: 14193-9.
76. Zhang J, Banfic H, Straforini F, Tosi L, Volinia S, Rittenhouse S E. A type II phosphoinositide 3-kinase is stimulated via activated integrin in platelets. A source of phosphatidylinositol 3-phosphate. J Biol Chem 1998; 273: 14081-4.
77. Hirsch E, Bosco O, Tropel P, Laffargue M, Calvez R, Altruda F, et al. Resistance to thromboembolism in PI3Kgamma-deficient mice. FASEB J 2001; 15: 2019-21.
78. Selheim F, Idsoe R, Fukami M H, Holmsen H, Vassbotn F S. Formation of PI3-kinase products in platelets by thrombin, but not collagen, is dependent on synergistic autocrine stimulation, particularly through secreted ADP. Biochem Biophys Res Commun 1999; 263: 780-5.
79. Chikumi H, Vazquez-Prado J. Servitja J M, Miyazaki H, Gutkind J S. Potent activation of RhoA by Galpha q and Gq-coupled receptors. J Biol Chem 2002; 277: 27130-4.
80. Nishioka H, Horiuchi H, Tabuchi A, Yoshioka A, Shirakawa R, Kita T. Small GTPase Rho regulates thrombin-induced platelet aggregation. Biochem Biophys Res Commun 2001; 280: 970-5.
81. Dorsam R T, Kim S, Jin J, Kunapuli S P. Coordinated signaling through both G12/13 and G(i) pathways is sufficient to activate GPIIb/IIIa in human platelets. J Biol Chem 2002; 277: 47588-95.
82. Manganello J M, Djellas Y, Borg C, Antonakis K, Le Breton G C. Cyclic AMP-dependent phosphorylation of thromboxane A(2) receptor-associated Galpha(13). J Biol Chem 1999; 274: 28003-10.
83. Manganello J M, Huang J S, Kozasa T, Voyno-Yasenetskaya T A, Le Breton G C. Protein kinase A-mediated phosphorylation of the Galpha 13 switch I region alters the Galpha beta gamma 13-G protein-coupled receptor complex and inhibits Rho activation. J Biol Chem 2003; 278: 124-30.
84. Dunlop P C, Leis L A, Johnson G J. Epinephrine correction of impaired platelet thromboxane receptor signaling. Am J Physiol Cell Physiol 2000; 279: C1760-C71.
85. Ogletree M L, Harris D N, Greenberg R, Haslanger M F. Nakane M. Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther 1985; 234: 435-41.
86. Kenakin T. Pharmacologic Analysis of Drug-Receptor Interaction. 2nd ed: New York: Raven Press, 1993, 278-322.
87. Takahara K, Murray R, FitzGerald G A, Fitzgerald D J. The response to thromboxane A2 analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems. J Biol Chem 1990; 265: 6836-44.
88. Morinelli T A, Halushka P V. Thromboxane-A2 prostaglandin-H2 receptors - characterization and antagonism. Trends Cardiovasc Med 1991; 1: 157-61.
89. Halushka P V, Allan C J, Davisbruno K L. Thromboxane A2 Receptors. J Lipid Mediators Cell Signal 1995; 12: 361-78.
90. Salzman E W, MacIntyre D E, Steer M L, Gordon J L. Effect on platelet activity of inhibition of adenylate cyclase. Thromb Res 1978; 13: 1089-101.
91. Imandt L, Tijhuis D, Wessels H, Haanen C. Lithium inhibits adenylate cyclase of human platelets. Thromb Haemost 1981; 45: 142-5. Platelets (September 2003) 14(6), 375-379